GSK Plummets To 10-Month Low As RSV, Shingles Vaccines Hit The Skids

GSK Plummets To 10-Month Low As RSV, Shingles Vaccines Hit The Skids · Investor's Business Daily
ALLISON GATLIN
1 min read

In This Article:

GSK stock plunged Wednesday after sales of its RSV vaccine, Arexvy, skidded and widely missed Wall Street's expectations.

Recommended Stories